Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy

NCT00000831 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

280

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Lamivudine
DRUG: Stavudine
DRUG: Zidovudine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)